Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

February 26, 2026 - 21:19

Syndax Pharmaceuticals has released its financial results for the fourth quarter and full year of 2025, reporting significant revenue growth driven by its two commercial products. The company also provided key updates on its clinical development pipeline.

For the final quarter of 2025, Syndax achieved total revenue of $68.7 million. Full-year revenue reached $172.4 million. This performance was fueled by robust sales of its flagship therapies. Revuforj® (revumenib) generated $44.2 million in net revenue for the fourth quarter, marking a substantial 38% increase over the prior quarter, with full-year sales totaling $124.8 million. Meanwhile, Niktimvo™ (axatilimab-csfr) contributed $56.0 million in fourth-quarter net revenue, a 22% sequential increase, culminating in $151.6 million for the full year. The company recognized $42.4 million in collaboration revenue related to Niktimvo in 2025.

Beyond financials, Syndax reported a major clinical milestone, having successfully completed enrollment in its Phase 2 trial evaluating axatilimab for the treatment of idiopathic pulmonary fibrosis (IPF). The company anticipates reporting topline data from this study in the fourth quarter of 2026. Management will further discuss these results and the business outlook in a conference call with investors and analysts.